Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on February 19, 2010, reporting events occurring on February 18, 2010. The filing serves as a Regulation FD disclosure regarding a company update on recently completed financings and the company's status on the NYSE Amex.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.01) containing details on recently completed financings, but the specific amounts and terms are not included in the body of this 8-K document.
Material Changes
- Financing Activity: The company completed financing activities as of February 18, 2010.
- Listing Status: The update addresses the company's status on the NYSE Amex.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard legal disclaimers. The document explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific amounts and terms of the "recently completed financings" by reviewing the attached Press Release (Exhibit 99.01).
- Confirm the current listing status of Neuralstem, Inc. on the NYSE Amex following the February 18, 2010 update.
- Note that the registrant name in the filing is Neuralstem, Inc., which differs from the metadata provided in the request.